SCHEMBL3374570

SCHEMBL3374570

CCOC(=O)C(Cc1ccc(OCCCc2csc(-c3ccccc3)n2)c(F)c1)OCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
THRB P10828 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
ATM Q13315 1/20 0.40
LMNA P02545 1/20 0.40
PPARG P37231 7/20 0.40
PPARA Q07869 6/20 0.40
TP53 P04637 4/20 0.40
NPC1 O15118 2/20 0.38
TSHR P16473 2/20 0.38
RAB9A P51151 2/20 0.38
PTPN2 P17706 1/20 0.38
PTPN1 P18031 1/20 0.38
PKM P14618 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372967 0.96 PTPN2 (0.42) MAPTTHRBSMN1; SMN2ATMLMNA
SCHEMBL3372389 0.93 PPARG (0.45) MAPTTHRBSMN1; SMN2ATMLMNA
SCHEMBL3372330 0.91 LMNA (0.38) MAPTTHRBLMNAPPARGPPARA
SCHEMBL3374527 0.91 RAB9A (0.44) MAPTSMN1; SMN2ATMLMNAPPARG
SCHEMBL3373587 0.89 LMNA (0.45) MAPTTHRBSMN1; SMN2LMNATP53
SCHEMBL3370731 0.89 PPARG (0.47) MAPTTHRBSMN1; SMN2ATMLMNA
SCHEMBL3374361 0.87 TP53 (0.38) MAPTTHRBLMNAPPARGPPARA
SCHEMBL3372462 0.87 TP53 (0.47) MAPTTHRBSMN1; SMN2LMNATP53
SCHEMBL3372856 0.86 TP53 (0.45) MAPTSMN1; SMN2LMNAPPARGPPARA
SCHEMBL3375172 0.86 TP53 (0.40) MAPTTHRBLMNAPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
EP-1537091-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2005-06-08 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed
WO-2004020420-A1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR MAPT 4327/4885THRB 58/4885SMN1; SMN2 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.